abstract Background: There are numerous potential treatments assessed for acute cerebral ischemia using animal models. This study aimed to assess the effect of these treatments in terms of infarct size and neurobehavioral change. This meta-analysis was conducted to determine if any of these treatments provide a superior benefit so that they might be used on humans. Methods: A systematic search was conducted using several electronic databases for controlled animal studies using only nonsurgical interventions for acute cerebral ischemia. A random-effects model was used. Results: After an extensive literature search, 145 studies were included in the analysis. These studies included 1408 treated animals and 1362 control animals. Treatments that had the most significant effect on neurobehavioral scales included insulin, various antagonists, including N-methyl-Daspartate (NMDA) receptor antagonist ACEA1021, calmodulin antagonist DY-9760e, and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist YM872, and antiviral agents. Treatments providing the greatest effect on infarct size included statins, sphingosine-1-phosphate agonist (fingolimod), alcohol, angiotensin, and leukotrienes. Treatments offering the greatest reduction in brain water content included various agonists, including sphingosine-1-phosphate agonist fingolimod, statins, and peroxisome proliferator-activated receptor gamma (PPAR-γ). Treatment groups with more than one study all had high heterogeneity (I 2 > 80%), however, using meta-regression we determined several sources of heterogeneity including sample size of the treatment and control groups, the occlusion time, but not the year when the study was conducted. Conclusions: Some treatments stand out when compared to others for acute cerebral ischemia in animals. Greater replication of treatment studies is required before any treatments are selected for future human trials.
Outcomes assessed
Three outcomes were to be assessed from these studies with one primary and two secondary outcomes. The primary outcome was neurobehavioral score and the secondary outcomes were (1) reduction in brain-water content and (2) the size of the infarct.
Data extraction
The data extraction was performed using a standardized data extraction form, collecting information on the publication year, sample size for treatment and control groups, country, animal type, statistical methods, occlusion time (mins), treatment, experimental time (days), neurobehavioral scores for treatment and control groups, infarct size for treatment and control groups, and brain-water content for treatment and control groups.
Quality assessment
No quality assessment was undertaken for these studies as none of them were randomized trials.
The studies were comparative in nature and did not involve any forms of randomization, blinding or allocation concealment. Thus, we thought that quality assessment would be too subjective for animal studies designed in such a way.
Statistical analysis

Meta-analysis
The studies compared the treatment group with the control group. The control group was either labeled as a control or sham. The primary outcomes assessed were neurobehavioral scores, with secondary outcomes (structural measures) either infarct volume or brain water content. Treatment and control groups were compared using a standard difference in means (std diff mean) for infarct volumes, neurobehavioral scores, and brain-water content using a random effects model [16] .
Assessment of heterogeneity
Heterogeneity was tested using the I 2 statistic, which represents the percentage of the total variability across studies which are due to heterogeneity [17] . I 2 values of 25, 50 and 75% corresponded to low, moderate and high degrees of heterogeneity, respectively.
Meta-regression
A mixed-effects meta-regression model was used for the meta-regression analysis. Metaregression was conducted to assess if we could identify any potential causes for any heterogeneity that may be present. The main factors analyzed using meta-regression were sample size of the treatment group, sample size of the control group, the occlusion time, and the year of publication for neurobehavioral score, infarct volume and brain water content.
Publication bias
The publication bias was quantified using the
Egger's regression model [18] , with the effect of bias assessed using the fail-safe number method. The fail-safe number was the number of studies that would need to be missed for the observed result to be nullified to statistical nonsignificance at the p < 0.05 level [19] . Publication bias is generally regarded as a concern if the fail-safe number is less than 5n+10, with n being the number of studies included in the meta-analysis. All analyses were performed with
Comprehensive Meta-Analysis software (version 2.0, 2005), Englewood, NJ, USA.
results
Search strategy
From 23053 studies initially identified, 145 met the inclusion criteria ( Fig. 1 ) .
Studies were excluded for the following reasons: no control group, abstract only, no data, hypothermia studies, genetic study, inappropriate study design, neonates, global ischemia, duplicates, language, radiology study, and cell-based studies. 
Study characteristics
The majority of the studies used rats as the animal model (n = 125, 89%), followed by mice (n = 13, 9%), with the remaining studies used mean -3.21), and North America (std diff mean -2.61).
There was publication bias present for the studies assessing infarct size (p < 0.001), and the fail-safe number was greater than 1000 (studies).
Brain water content
There were 15 studies that assessed brain water content for 13 different treatments. Further research should be conducted into these treatments as potential options for the management of acute cerebral ischemia among humans. Additional mechanistic evidence is required for these potential treatments [161, 162] . For example, recent human studies have reported that statins improve 2-year survival and 2-year functional outcome [163] [164] [165] . These data require replication in other populations and long-term follow-up to assess outcomes in these patients.
This study had a number of strengths. The PRISMA guidelines were followed, although no specific guidelines were followed for metaanalysis of animal studies. A thorough search was performed using multiple databases and we imposed no word restrictions. However, studies that did not include a control group were excluded. The use of an internal control group is recognized as a more statistically robust way of study design. There were also some limitations to this study. 
